Skip to main content

Table 3 Disease prevention policy models

From: Policy models for preventative interventions in cardiometabolic diseases: a systematic review

 

DYNAMO-HIA

CVD Policy Model

CHD Policy Model

Impact CHD

CVD-Predict

Scottish Policy model

SPHR Diabetes Model

Scope

NCDs (non-communicable diseases) including CVD, diabetes, and risk factors

CVD and related risk factors, focusing on prevention and treatment strategies

CVD and related risk factors, focusing on prevention and treatment strategies

CHD and CVD interventions, evaluating their effectiveness

CVD with a focus on prediction and risk stratification for better preventive measures

Public health with a specific focus on CVD and associated risk factors in Scotland

Diabetes and related risk factors, focusing on prevention, management, and health outcomes

Applicability

Primarily European countries, but adaptable globally

Primarily used in the US

Primarily used in the US

Applicable globally with regional adaptations

Applicable globally, with a focus on predictive analytics

Primarily used in Scotland

Primarily used in the UK

Data sources

European health surveys, epidemiological studies, and literature

National health surveys, clinical trials, epidemiological studies

National health surveys, clinical trials, epidemiological studies

National health surveys, clinical trials, epidemiological studies

National health surveys, clinical trials, epidemiological studies

Scottish health surveys, hospital records, national statistics

National health surveys, clinical trials, epidemiological studies

Outcome of interests

Estimates incidence, prevalence, mortality, QALY health impact, under various policy scenarios

Estimates incidence, prevalence, mortality, and healthcare costs, cost -effectiveness

Estimates incidence, prevalence, mortality, QALY, health disparities healthcare costs of CHD and stroke

Estimates incidence, mortality, hospital admissions, cost-effectiveness

Estimates incidence, risk prediction, mortality, and health care costs, health outcomes, cost -effectiveness

Estimates incidence, mortality, hospital admissions, QALE, cost-effectiveness

Estimates incidence, prevalence, mortality, QALY, cost-effectiveness

Key strengths

Comprehensive modelling of individual and population-level effects; integration of multiple risk factors and interventions for a nuanced analysis across health outcomes

Robust framework for evaluating interventions at a population level; flexible to include various types of interventions; extensive validation with US data

Extensive validation with US data; comprehensive risk factor integration

Comprehensive evaluation of interventions; focus on real-world applicability; extensive data sources

High granularity of individual risk prediction; ability to incorporate large datasets and update predictions with real-time data

Robust dataset specific to Scotland; focus on real-world applicability and policy impact; capable of addressing health inequalities and informing equitable policy decisions

Focus on diabetes-specific interventions and outcomes; ability to assess a wide range of potential interventions and their population-level impacts

Key weaknesses

Complexity in adapting to non-European contexts– Requires extensive data input

Can be complex to adapt to new populations or to integrate novel interventions without substantial effort and data

Requires extensive and high-quality data for accurate projections; complexity of model may limit its accessibility for non-specialists

May not account for all complex interactions between risk factors and interventions; data limitations can affect accuracy

Requires access to high-quality, comprehensive health records; model accuracy can be affected by missing or inaccurate data

Limited to the Scottish population, which may limit generalisability to other regions; data limitations outside of Scotland may affect model accuracy

Complexity and data requirements can limit accessibility for some users; relies on accurate input data for precise predictions